Chromogenic in situ hybridization and p16/Ki67 dual staining on formalin-fixed paraffin-embedded cervical specimens: Correlation with HPV-DNA test, E6/E7 mRNA test, and potential clinical applications

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Zappacosta, Roberta ^a   Colasante, Antonella ^b   Viola, Patrizia ^b   D'Antuono, Tommaso ^b   Lattanzio, Giuseppe ^b   Capanna, Serena ^b   Gatta, Daniela Maria Pia ^a   Rosini, Sandra ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SS Annunziata Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; ONCOPROTEIN; PARAFFIN; VIRUS DNA;

ARTICLE; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PARAFFIN EMBEDDING; UTERINE CERVICAL NEOPLASMS;

EID: 84893720202     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/453606     Document Type: Article

References (37)

1. Zappacosta R., Rosini S., Cervical cancer screening: from molecular basis to diagnostic practice, going through new technologies. Technology in Cancer Resear (Pubitemid 351847606)
2. Cuzick J., Clavel C., Petry K., Meijer C. J. L. M., Hoyer H., Ratnam S., Szarewski A., Birembaut P., Kulasingam S., Sasieni P., Iftner T., Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer 2006 119 5 1095 1101 2-s2.0-33746349573 10.1002/ijc.21955 (Pubitemid 44116919)
3. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M., Dillner J., Meijer C. J. L. M., Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008 26 10 K29 K41 2-s2.0-50849143179 10.1016/j.vaccine.2008. 06.019
4. Giorgi Rossi P., Benevolo M., Vocaturo A., Prognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study. PLOS One 2013 8 2 54 62
5. Guo M., Gong Y., Deavers M., Silva E. G., Yee J. J., Cogdell D. E., Luthra R., Lin E., Hung C. L., Zhang W., Sneige N., Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. Journal of Clinical Microbiology 2008 46 1 274 280 2-s2.0-38149072925 10.1128/JCM.01299-07
6. Dabić M. M., Hlupić L., Babić D., Jukić S., Seiwerth S., Comparison of polymerase chain reaction and catalyzed signal amplification in Situ hybridization methods for human papillomavirus detection in paraffin-embedded cervical preneoplastic and neoplastic lesions. Archives of Medical Research 2004 35 6 511 516 2-s2.0-22944440729 10.1016/j.arcmed.2004.07. 004 (Pubitemid 41043622)
7. Evans M. F., Mount S. L., Beatty B. G., Cooper K., Biotinyl-tyramide- based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia. Modern Pathology 2002 15 12 1339 1347 2-s2.0-0036905284 10.1038/modpathol.3880698 (Pubitemid 35463003)
8. Meissner J. D., Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. Journal of General Virology 1999 80 7 1725 1733 2-s2.0-0032987565 (Pubitemid 29319864)
9. Petry K. U., Schmidt D., Scherbring S., Luyten A., Reinecke-Lüthge A., Bergeron C., Kommoss F., Löning T., Ordi J., Regauer S., Ridder R., Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecologic Oncology 2011 121 3 505 509 2-s2.0-79957472045 10.1016/j.ygyno.2011.02.033
10. Schmidt D., Bergeron C., Denton K. J., Ridder R., p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathology 2011 119 3 158 166 2-s2.0-80051606647 10.1002/cncy.20140
11. Tinelli A., Leo G., Pisanò M., Storelli F., Leo S., Vergara D., Malvasi A., HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions. Current Pharmaceutical Biotechnology 2009 10 8 767 771 2-s2.0-73649105111 10.2174/138920109789978739
12. Landis J. R., Koch G. G., The measurement of observer agreement for categorical data. Biometrics 1977 33 1 159 174 2-s2.0-0017360990 (Pubitemid 8054849)
13. DeLong E. R., DeLong D. M., Clarke-Pearson D. L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988 44 3 837 845 2-s2.0-0023710206
14. Snijders P. J. F., van den Brule A. J. C., Meijer C. J. L. M., The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. Journal of Pathology 2003 201 1 1 6 2-s2.0-0141626740 10.1002/path.1433 (Pubitemid 37121197)
15. Zappacosta R., Caraceni D., Ciccocioppo L., Ottaviantonio M., Conti F., Andreozzi S., Petrucci F., Rosini S., Is HPV-DNA testing a useful tool in predicting low-grade squamous intraepithelial lesion outcome? A retrospective longitudinal study. International Journal of Immunopathology and Pharmacology 2010 23 1 317 326 2-s2.0-77951756281
16. Qu W., Jiang G., Cruz Y., Chang C. J., Ho G. Y. F., Klein R. S., Burk R. D., PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. Journal of Clinical Microbiology 1997 35 6 1304 1310 2-s2.0-0030949357 (Pubitemid 27216785)
17. Arbyn M., Sasieni P., Meijer C. J. L. M., Clavel C., Koliopoulos G., Dillner J., Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006 24 supplement 3 S78 S89 2-s2.0-33747890825 10.1016/j.vaccine.2006.05.117 (Pubitemid 44293029)
18. Evans M. F., Cooper K., Human papillomavirus integration: detection by in situ hybridization and potential clinical application. Journal of Pathology 2004 202 1 1 4 2-s2.0-0346656563 10.1002/path.1519 (Pubitemid 38072839)
19. Montag M., Blankenstein T. J. F., Shabani N., Brüning A., Mylonas I., Evaluation of two commercialised in situ hybridisation assays for detecting HPV-DNA in formalin-fixed, paraffin-embedded tissue. Archives of Gynecology and Obstetrics 2011 284 4 999 1005 2-s2.0-84855728475 10.1007/s00404-010-1771-z
20. Kuo K. T., Hsiao C. H., Lin C. H., Kuo L., Huang S., Lin M., The biomarkers of human papillomavirus infection in tonsillar squamous cell carcinoma-molecular basis and predicting favorable outcome. Modern Pathology 2008 21 4 376 386 2-s2.0-41149173816 10.1038/modpathol.3800979 (Pubitemid 351441025)
21. Luginbuhl A., Sanders M., Spiro J. D., Prevalence, morphology, and prognosis of human papillomavirus in tonsillar cancer. Annals of Otology, Rhinology and Laryngology 2009 118 10 742 749 2-s2.0-70350512134
22. Evans M. F., Aliesky H. A., Cooper K., Optimization of biotinyl-tyramide-based in situ hybridization for sensitive background-free applications on formalin-fixed, paraffin-embedded tissue specimens. BMC Clinical Pathology 2003 3 1 1 17 2-s2.0-0347908868 10.1186/1472-6890-3-1
23. Evans M. F., Matthews A., Kandil D., Adamson C. S., Trotman W. E., Cooper K., Discrimination of "Driver" and "Passenger" HPV in tonsillar carcinomas by the polymerase chain reaction, chromogenic in situ hybridization, and p 16 INK 4 a immunohistochemistry. Head and Neck Pathology 2011 5 4 344 348 2-s2.0-80955144373 10.1007/s12105-011-0282-y
24. Clifford G. M., Smith J. S., Plummer M., Muñoz N., Franceschi S., Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. British Journal of Cancer 2003 88 1 63 69 2-s2.0-0037434411 10.1038/sj.bjc.6600688 (Pubitemid 36241220)
25. Kraus L., Molden T., Holm R., Lie A. K., Karlsen F., Kristensen G. B., Skomedal H., Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. Journal of Clinical Microbiology 2006 44 4 1310 1317 2-s2.0-33645937963 10.1128/JCM.44.4.1310-1317. 2006
26. de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., Bosch F. X., Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases 2007 7 7 453 459 2-s2.0-34250736244 10.1016/S1473-3099(07)70158-5 (Pubitemid 46962343)
27. Gallo G., Bibbo M., Bagella L., Zamparelli A., Sanseverino F., Giovagnoli M. R., Vecchione A., Giordano A., Study of viral integration of HPV-16 in young patients with LSIL. Journal of Clinical Pathology 2003 56 7 532 536 2-s2.0-0037668491 10.1136/jcp.56.7.532 (Pubitemid 36819426)
28. Murphy N., Ring M., Heffron C. C. B. B., King B., Killalea A. G., Hughes C., Martin C. M., McGuinness E., Sheils O., O'Leary J. J., p 16 INK 4 a, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. Journal of Clinical Pathology 2005 58 5 525 534 2-s2.0-20844443130 10.1136/jcp.2004.018895 (Pubitemid 40646875)
29. Wang S. S., Trunk M., Schiffman M., Herrero R., Sherman M. E., Burk R. D., Hildesheim A., Bratti M. C., Wright T., Rodriguez A. C., Chen S., Reichert A., Von Knebel Doeberitz C., Ridder R., Von Knebel Doeberitz M., Validation of p 16 INK 4 a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiology Biomarkers and Prevention 2004 13 8 1355 1360 2-s2.0-7044231257 (Pubitemid 39071561)
30. Tsoumpou I., Arbyn M., Kyrgiou M., Wentzensen N., Koliopoulos G., Martin-Hirsch P., Malamou-Mitsi V., Paraskevaidis E., p 16 INK 4 a immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treatment Reviews 2009 35 3 210 220 2-s2.0-64249149339 10.1016/j.ctrv.2008.10.005
31. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., Dallenbach-Hellweg G., Schmidt D., Von Doeberitz M. K., Overexpression of p 16 INK 4 a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. International Journal of Cancer 2001 92 2 276 284 2-s2.0-0035871985 10.1002/ijc.1174 (Pubitemid 32225381)
32. Tsoumpou I., Valasoulis G., Founta C., Kyrgiou M., Nasioutziki M., Daponte A., Koliopoulos G., Malamou-Mitsi V., Karakitsos P., Paraskevaidis E., High-risk human papillomavirus DNA test and p 16 INK 4 a in the triage of LSIL: a prospective diagnostic study. Gynecologic Oncology 2011 121 1 49 53 2-s2.0-79952818082 10.1016/j.ygyno.2010.12.002
33. Denton K. J., Bergeron C., Klement P., Trunk M. J., Keller T., Ridder R., The sensitivity and specificity of p 16 INK 4 a cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL Pap cytology results. American Journal of Clinical Pathology 2010 134 1 12 21 2-s2.0-77954532457 10.1309/AJCP3CD9YKYFJDQL
34. Martin C. M., O'Leary J. J., Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Practice & Research Clinical Obstetrics and Gynaecology 2011 25 5 605 615 2-s2.0-84858261304
35. Meyer J. L., Hanlon D. W., Andersen B. T., Rasmussen O. F., Bisgaard K., Evaluation of p 16 INK 4 a expression in ThinPrep cervical specimens with the CINtec p 16 INK 4 a assay: correlation with biopsy follow-up results. Cancer 2007 111 2 83 92 2-s2.0-34247466557 10.1002/cncr.22580 (Pubitemid 46648406)
36. del Pino M., Garcia S., Fusté V., Alonso I., Fusté P., Torné A., Ordi J., Value of p 16 INK 4 a as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. American Journal of Obstetrics and Gynecology 2009 201 5 488e1 488e7 2-s2.0-70350565964 10.1016/j.ajog.2009.05.046
37. Stewart L. M., Einstein M. H., Huh W. K., Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease 2013 17 1 27